Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Exercise for individuals with bone metastases: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. FDG-PET in the clinical management of Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patients in phase 1 cancer trials: psychological distress and understanding of trial information

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Transient congenital hyperinsulinism and hemolytic disease of a newborn despite rhesus D prophylaxis: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Accurate data on HER2 positivity in esophageal squamous cell carcinoma patients (ESCC) is lacking. We conducted a systematic review and meta-analysis (Single Incidence Rates; metarate package, R) to examine the prevalence of HER2 in ESCC. Data on in situ hybridization (ISH) and immunohistochemistry (IHC) were extracted to derive pooled prevalence estimates, characteristics of the studies were extracted for subgroup analysis. Eighteen studies with 1505 patients were identified. HER2 gene amplification by ISH were prevalent in 10 % (95 % CI 6.9 %-15 %). Prevalence of HER2 overexpression (IHC3+) and borderline HER2 expression (IHC2+) were 6 % (95 % CI: 3.5 %-8.7 %) and 10 % (95 % CI: 6.0 %-17 %), respectively. An estimated 8.6 % (95 % CI: 5.5 %-13 %) of ESCC were HER2 positive using initial IHC followed by reflex ISH confirmation of borderline HER2 expression. In conclusion: Estimated prevalence of HER 2 positivity in ESCC were 10 % assessed by ISH and 8.6 % assessed by initial IHC followed by ISH.

OriginalsprogEngelsk
Artikelnummer103339
TidsskriftCritical Reviews in Oncology/Hematology
Vol/bind161
Sider (fra-til)103339
ISSN1040-8428
DOI
StatusUdgivet - maj 2021

Bibliografisk note

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

ID: 70122885